摘要:
The present invention relates to compounds of the general formula wherein
R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen; R 2 is hydrogen, lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-methanol or -NHCH 2 CHROH; R 3 is hydrogen or halogen; R is hydrogen, lower alkyl or -CH 2 OH; n is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity in mediating processes underlying development of CNS as well as learning and memory formation.
摘要:
The invention relates to compounds of formula wherein
R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen; R 2 is phenyl, optionally substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, lower alkyl-amino or di-lower alkyl-amino 2,3 -dihydro-benzofuran-5-yl, chroman-6-yl, naphthalen-2-yl, indan-5-yl, lower alkenyl-phenyl, 5,6,7,8-tetrahydro-naphthalenyl, 2,3-dihydro-isoindol-2-yl, 1,2,3,4-tetrahydro-naphthalenyl, benzofuran-2-yl, benzo[b]thiophen-2-yl, lower alkyl-phenyl, 3,4-dihydro-1H-isoquinolin-2-yl or thiophen-3-yl; R 3 and R 4 are independently from each other hydrogen or lower alkyl; R 5 is hydrogen, lower alkyl, -CH 2 OH or -CH 2 NR 6 R 7 ; R 6 and R 7 are independently from each other hydrogen, lower alkyl, - (CH 2 ) n -phenyl, cycloalkyl, -(CH 2 ) m -morpholinyl or form together with the N-atom a saturated ring with 4-6 C-atoms; n is 0-3; m is 2 or 3; X is -NR 8 - or -O-; or X and R 5 are together >N(CH 2 ) 2 -; or X and R 3 are together >N(CH 2 ) 3 -; and R 8 is hydrogen or lower alkyl; and to pharmaceutically acceptable acid addition salts thereof, with the exception of the following compounds
(6-chloro-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; (6-methyl-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; (6-methoxy-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; and (8-methoxy-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol, which may be used for the treatment of diseases, which relate to the NMDA receptor specific blockers.
摘要:
The present invention relates to compounds of the general formula wherein
R 1 ― R 4 signify independently hydrogen, -CF 3 , -OCF 3 , OCHF 2 , -OCH 2 F, lower alkyl, lower alkoxy, halogen, hydroxy, phenyl, benzyl, amino, nitro, pyrrol-1-yl, lower alkyl-sulfonyl, lower alkyl-sulfanyl, cyano or benzyloxy; or R 2 and R 3 may be together ―O-(CH 2 ) 2 -O-, -O-CH 2 -O-, -O-(CH 2 ) 2 -, -(CH 2 ) 3 - or ―CH=CH-CH=CH-; X signifies ―N=, -N(R 8 )- or ―CH=; Y signifies ―N=, =N-, -N(R 8 )- or ―CH=; wherein one of X or Y has to be nitrogen; R 5 signifies the group wherein R 6 and R 7 signify independently from each other hydrogen, lower alkyl, -C(O)-lower alkyl, hydroxy-lower alkyl, lower alkenyl, -C(O)CH 2 OH or R 6 and R 7 may be together with the N-atom ―(CH 2 ) n -, -(CH 2 ) 2 -O-(CH 2 ) 2 -, -CH 2 -CH=CH-CH 2 , -CH 2 -CH[OC(O)CH 3 ]-(CH 2 ) 2 , -CH 2 -CH[NHC(O)CH 3 ]-(CH 2 ) 2 , -O-(CH 2 ) 3 -, -CH 2 -CH(OCH 3 )-(CH 2 ) 2 -, -CH 2 -CH(halogen)-(CH 2 ) 2 -, -(CH 2 ) 2 -CH(O-phenyl)-(CH 2 ) 2 -, -(CH 2 ) 2 -N(CHO)-(CH 2 ) 2 -, -(CH 2 ) 2 -N(COCH 3 )-(CH 2 ) 2 -, -CH 2 -CH(OH)-(CH 2 ) 3 -, -(CH 2 ) 2 -CH(OH)-(CH 2 ) 2 - or -(CH 2 ) 2 -N(benzyl)-CH 2 ) 2 -; n signifies 3 to 5; and R 8 signifies hydrogen, lower alkyl, lower alkenyl, lower alkinyl, -(CH 2 ) m -O-lower alkyl, -(CH 2 ) m -OH, -(CH 2 ) m -CHF 2 , -(CH 2 ) m -CH 2 F, -(CH 2 ) m -C(O)-lower alkyl, - (CH 2 ) m -C(O)O-lower alkyl, -(CH 2 ) m -CH(OH)-lower alkyl, -(CH 2 ) m -CH(OH)-(CH 2 ) m OH, -(CH 2 ) m -C 6 H 5 , which phenyl ring is optionally substituted by lower alkyl, lower alkoxy or hydroxy, -(CH 2 ) m -C(=CH 2 )-lower alkyl, - (CH 2 ) m -cycloalkyl, -(CH 2 ) m -CN, -(CH 2 ) m -pyridin-4-yl, -(CH 2 ) m -pyridin-3-yl or - (CH 2 ) m -pyridin-2-yl; m signifies 0 to 4; and to their pharmaceutically acceptable acid addition salts. These compounds may be used for the treatment of diseases related to the NMDA receptor subtype selective blockers.